155 related articles for article (PubMed ID: 37607946)
21. Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy.
Yang Y; Meng WJ; Wang ZQ
Front Biosci (Landmark Ed); 2023 Apr; 28(4):69. PubMed ID: 37114536
[TBL] [Abstract][Full Text] [Related]
22. Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer.
Quan Y; He J; Zou Q; Zhang L; Sun Q; Huang H; Li W; Xie K; Wei F
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597850
[TBL] [Abstract][Full Text] [Related]
23. PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients.
Wang Y; Chen H; Jiao X; Wu L; Yang Y; Zhang J; Wu L; Liu C; Zhuo N; Li S; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Lu Z; Zhang H; Shen L
Cancer Immunol Immunother; 2022 Jan; 71(1):111-120. PubMed ID: 34028566
[TBL] [Abstract][Full Text] [Related]
24. Insight into immune checkpoint inhibitor therapy for colorectal cancer from the perspective of circadian clocks.
Liu Y; Wang Z; Hao H; Wang Y; Hua L
Immunology; 2023 Sep; 170(1):13-27. PubMed ID: 37114514
[TBL] [Abstract][Full Text] [Related]
25. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer.
Liu C; Xiao H; Cui L; Fang L; Han S; Ruan Y; Zhao W; Zhang Y
Front Immunol; 2022; 13():1039631. PubMed ID: 36479108
[TBL] [Abstract][Full Text] [Related]
27. Histone Methyltransferase SETDB1 Promotes Immune Evasion in Colorectal Cancer
Tian J; Wang W; Zhu J; Zhuang Y; Qi C; Cai Z; Yan W; Lu W; Shang A
J Immunol Res; 2022; 2022():4012920. PubMed ID: 35497876
[TBL] [Abstract][Full Text] [Related]
28. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer.
Huang L; Zhao H; Shan M; Chen H; Xu B; He Y; Zhao Y; Liu Z; Chen J; Xu Q
Cancer Med; 2022 Dec; 11(23):4575-4587. PubMed ID: 35762456
[TBL] [Abstract][Full Text] [Related]
30. Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action.
Take Y; Koizumi S; Nagahisa A
Front Immunol; 2020; 11():324. PubMed ID: 32210957
[TBL] [Abstract][Full Text] [Related]
31. Intrinsic β-catenin signaling suppresses CD8
Xue J; Yu X; Xue L; Ge X; Zhao W; Peng W
Biomed Pharmacother; 2019 Jul; 115():108921. PubMed ID: 31078045
[TBL] [Abstract][Full Text] [Related]
32. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.
Xu B; Yuan L; Gao Q; Yuan P; Zhao P; Yuan H; Fan H; Li T; Qin P; Han L; Fang W; Suo Z
Oncotarget; 2015 Aug; 6(24):20592-603. PubMed ID: 26008981
[TBL] [Abstract][Full Text] [Related]
33. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.
Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P
Front Immunol; 2022; 13():809971. PubMed ID: 35185898
[TBL] [Abstract][Full Text] [Related]
34. Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors.
Lin Y; Luo S; Luo M; Lu X; Li Q; Xie M; Huang Y; Liao X; Zhang Y; Li Y; Liang R
Mol Carcinog; 2023 Sep; 62(9):1271-1283. PubMed ID: 37232365
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant immunotherapy in colorectal cancer beyond immune checkpoint inhibitors: emerging from bench to bedside.
Kanani A; Veen T; Alexeeva M; Lea D; Søreide K
Minerva Surg; 2023 Aug; 78(4):385-400. PubMed ID: 36940110
[TBL] [Abstract][Full Text] [Related]
36. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
37. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
Zou J; Xia H; Zhang C; Xu H; Tang Q; Zhu G; Li J; Bi F
Cancer Sci; 2021 Jul; 112(7):2664-2678. PubMed ID: 33934451
[TBL] [Abstract][Full Text] [Related]
38. Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8
Cagnoni AJ; Giribaldi ML; Blidner AG; Cutine AM; Gatto SG; Morales RM; Salatino M; Abba MC; Croci DO; Mariño KV; Rabinovich GA
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006646
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
[TBL] [Abstract][Full Text] [Related]
40. Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation.
Zhang B; Li J; Hua Q; Wang H; Xu G; Chen J; Zhu Y; Li R; Liang Q; Wang L; Jin M; Tang J; Lin Z; Zhao L; Zhang D; Yu D; Ren J; Zhang T
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36596591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
